[Bounderies of the authorization to market and the therapeutic impass].
Samama, C M
[Bounderies of the authorization to market and the therapeutic impass]. [electronic resource] - Annales francaises d'anesthesie et de reanimation Jun 2001 - 507-8 p. digital
Publication Type: Editorial
0750-7658
10.1016/s0750-7658(01)00438-5 doi
Anticoagulants--adverse effects
Chondroitin Sulfates--adverse effects
Dermatan Sulfate--adverse effects
Drug Approval--legislation & jurisprudence
Drug Combinations
France
Heparin--adverse effects
Heparitin Sulfate--adverse effects
Hirudin Therapy
Hirudins--adverse effects
Humans
Recombinant Proteins--adverse effects
[Bounderies of the authorization to market and the therapeutic impass]. [electronic resource] - Annales francaises d'anesthesie et de reanimation Jun 2001 - 507-8 p. digital
Publication Type: Editorial
0750-7658
10.1016/s0750-7658(01)00438-5 doi
Anticoagulants--adverse effects
Chondroitin Sulfates--adverse effects
Dermatan Sulfate--adverse effects
Drug Approval--legislation & jurisprudence
Drug Combinations
France
Heparin--adverse effects
Heparitin Sulfate--adverse effects
Hirudin Therapy
Hirudins--adverse effects
Humans
Recombinant Proteins--adverse effects